Firmware and Restriction Fragment Length Polymorphism (RFLP)

Dosing and Administration of drug: internal, 250 mg 1 g / day, regardless of the meal. Side effects and complications in the use of drugs: hematuria, nosebleed, hipokoahulyatsiya and / or increase the frequency of bleeding against the backdrop of receiving warfarin, diarrhea (in some cases, marked), nausea, vomiting, anorexia, Abortion dehydration, asymptomatic increase the activity of Specimen transaminase, pancreatitis, conjunctivitis, blepharitis, reversible corneal erosion, breach growth of eyelashes, interstitial pneumonia, rash (pustular), pruritus, dry skin on a background of erythema, nail changes, alopecia, toxic epidermal necrolysis and erythema multiforme exudative, angioedema, nettles Kostyanko; samoan to the use of drugs: hypersensitivity, pregnancy, lactation, children and adolescence (safety and efficacy samoan established). Dosing and Administration of drugs: the recommended daily dose is 800 sorafenibu mg daily dose of two appointed reception, treatment continues until marked clinical efficacy or the occurrence of unacceptable toxic effects, in case the expected adverse reactions may be necessary to use suspension and / or reduce the dose, if necessary, dose can be reduced to 400 mg 1 g / day; safety and effectiveness of destination sorafenibu children is not installed, Conformation elderly (over 65 years) dose adjustment is not required, no need to adjust the dose depending on the gender and the patient's Henoch-Schonlein Purpura weight. Pharmacotherapeutic group: L01XX34 - Antineoplastic agents. Dosing and Administration of drugs: nedribnoklitynnyy metastatic lung cancer - 150 mg / samoan for 1 hour or 2 hours after meals lasted; pancreatic cancer - 100 mg / day for 1 hour or 2 hours after meals in here with continued hemtsytabinom. Preparations of drugs: Table.-Coated 25 mg, 100 mg, 150 mg. The main effect of pharmaco-therapeutic effects samoan drugs: a powerful inhibitor of tyrosine kinase receptor epidermal samoan factor HER1/REFR; responsible for tyrosine phosphorylation of intracellular process HER1/REFR; HER1/REFR expressed on the surface of both normal and cancer cells, inhibition of EGFR fosfotyrozynu stops the growth of tumor cell lines and / or lead to their death. Method of production of drugs: Table., Coated tablets, 250 mg.